Skip to main content
SpringerLink
Log in
Book cover

Cancer Immunology pp 319–332Cite as

Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas

  • Chapter

  • 2903 Accesses

Abstract

Sarcomas have long been recognized as being responsive to manipulations of the immune system. Dating back to over a century ago, Coley’s toxin was one of the first forms of immunotherapy for the treatment of sarcoma. With advancements in molecular oncology and the identification of specific sarcoma antigens, direct experimentation has been made possible in a variety of preclinical animal models. Discoveries from the laboratory have led to novel immunotherapeutic approaches to the treatment of sarcoma which are rapidly evolving.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154–8.

    PubMed Central  PubMed  Google Scholar 

  2. Coley II WB. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14(3):199–220.

    PubMed Central  CAS  PubMed  Google Scholar 

  3. Nauts HC, McLaren JR. Coley toxins–the first century. Adv Exp Med Biol. 1990;267:483–500.

    CAS  PubMed  Google Scholar 

  4. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011;30(1):16–34.

    CAS  PubMed  Google Scholar 

  5. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9(1):57–63.

    CAS  PubMed  Google Scholar 

  6. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1(6):949–64.

    PubMed Central  CAS  PubMed  Google Scholar 

  7. Rossol M, Heine H, Meusch U, Quandt D, Klein C, Sweet MJ, et al. LPS-induced cytokine production in human monocytes and macrophages. Crit Rev Immunol. 2011;31(5):379–446.

    CAS  PubMed  Google Scholar 

  8. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother. 2010;59(10):1573–82.

    CAS  PubMed  Google Scholar 

  9. Bjorkbacka H, Fitzgerald KA, Huet F, Li X, Gregory JA, Lee MA, et al. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics. 2004;19(3):319–30.

    PubMed  Google Scholar 

  10. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194(6):863–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  11. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419–26.

    CAS  PubMed  Google Scholar 

  12. Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol. 2011;2011:609579.

    PubMed Central  PubMed  Google Scholar 

  13. Sato Y, Goto Y, Narita N, Hoon DS. Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2009;2 Suppl 1:205–14.

    PubMed Central  PubMed  Google Scholar 

  14. Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013;93(6):847–63.

    PubMed Central  CAS  PubMed  Google Scholar 

  15. Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, et al. Molecular pathways: toll-like receptors in the tumor microenvironment–poor prognosis or new therapeutic opportunity. Clin Cancer Res. 2013;19(6):1340–6.

    CAS  PubMed  Google Scholar 

  16. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol. 2010;667:111–23.

    PubMed  Google Scholar 

  17. Celestin Schartz NE, Chevret S, Paz C, Kerob D, Verola O, Morel P, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi’s sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. J Am Acad Dermatol. 2008;58(4):585–91.

    PubMed  Google Scholar 

  18. Chen YT, Gure AO, Scanlan MJ. Serological analysis of expression cDNA libraries (SEREX): an immunoscreening technique for identifying immunogenic tumor antigens. Meth Mol Med. 2005;103:207–16.

    CAS  Google Scholar 

  19. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100(11):2014–21.

    CAS  PubMed  Google Scholar 

  20. Cebon J, Knights A, Ebert L, Jackson H, Chen W. Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. Expert Rev Vac. 2010;9(6):617–29.

    CAS  Google Scholar 

  21. Lai JP, Rosenberg AZ, Miettinen MM, Lee CC. NY-ESO-1 expression in sarcomas: a diagnostic marker and immunotherapy target. Oncoimmunology. 2012;1(8):1409–10.

    PubMed Central  PubMed  Google Scholar 

  22. Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012;118(18):4564–70.

    PubMed Central  CAS  PubMed  Google Scholar 

  23. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A. 2008;105(51):20410–5.

    PubMed Central  CAS  PubMed  Google Scholar 

  24. Smith HA, McNeel DG. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol. 2010;2010:150591.

    PubMed Central  PubMed  Google Scholar 

  25. Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res. 2008;466(9):2156–67.

    PubMed Central  PubMed  Google Scholar 

  26. Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J. 1995;14(10):2333–40.

    PubMed Central  CAS  PubMed  Google Scholar 

  27. Nagai M, Tanaka S, Tsuda M, Endo S, Kato H, Sonobe H, et al. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci U S A. 2001;98(7):3843–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  28. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14(18):2175–88.

    Google Scholar 

  29. Li XQ, Hisaoka M, Shi DR, Zhu XZ, Hashimoto H. Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. Hum Pathol. 2004;35(6):711–21.

    CAS  PubMed  Google Scholar 

  30. Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363(18):1727–33.

    PubMed Central  CAS  PubMed  Google Scholar 

  31. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105–11.

    PubMed Central  CAS  PubMed  Google Scholar 

  32. Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707–19.

    CAS  PubMed  Google Scholar 

  33. Radu O, Pantanowitz L. Kaposi sarcoma. Arch Pathol Lab Med. 2013;137(2):289–94.

    CAS  PubMed  Google Scholar 

  34. Krown SE, Roy D, Lee JY, Dezube BJ, Reid EG, Venkataramanan R, et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr. 2012;59(5):447–54.

    PubMed Central  CAS  PubMed  Google Scholar 

  35. Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin AG, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma–associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr. 2002;31(4):384–90.

    CAS  PubMed  Google Scholar 

  36. Wilkinson J, Cope A, Gill J, Bourboulia D, Hayes P, Imami N, et al. Identification of Kaposi’s sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol. 2002;76(6):2634–40.

    PubMed Central  CAS  PubMed  Google Scholar 

  37. Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi’s sarcoma and primary effusion lymphoma. Curr Opin Oncol. 2005;17(5):447–55.

    CAS  PubMed  Google Scholar 

  38. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006;66(7):3351–4.

    CAS  PubMed  Google Scholar 

  39. Dodd RD, Mito JK, Kirsch DG. Animal models of soft-tissue sarcoma. Dis Model Mech. 2010;3(9–10):557–66.

    PubMed Central  CAS  PubMed  Google Scholar 

  40. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 1943;3(5):326–33.

    Google Scholar 

  41. Malins DC, Anderson KM, Gilman NK, Green VM, Barker EA, Hellstrom KE. Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci U S A. 2004;101(29):10721–5.

    PubMed Central  CAS  PubMed  Google Scholar 

  42. Shimokado K, Watanabe H, Sumii M, Miyagawa K, Kamiya K, Dohi K, et al. p53 gene mutation and loss of heterozygosity of chromosome 11 in methylcholanthrene-induced mouse sarcomas. Jpn J Cancer Res. 1998;89(3):269–77.

    CAS  PubMed  Google Scholar 

  43. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215–21.

    CAS  PubMed  Google Scholar 

  44. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286(5447):2172–6.

    CAS  PubMed  Google Scholar 

  45. Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP, et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med. 2007;13(8):992–7.

    CAS  PubMed  Google Scholar 

  46. Shastri N, Schwab S, Serwold T. Producing nature’s gene-chips: the generation of peptides for display by MHC class I molecules. Ann Rev Immunol. 2002;20:463–93.

    CAS  Google Scholar 

  47. Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to infection. Ann Rev Immunol. 2000;18:275–308.

    CAS  Google Scholar 

  48. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52.

    CAS  PubMed  Google Scholar 

  49. Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet. 2000;356(9236):1163–5.

    CAS  PubMed  Google Scholar 

  50. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181–273.

    CAS  PubMed  Google Scholar 

  51. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother. 2004;53(10):904–10.

    CAS  PubMed  Google Scholar 

  52. Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol. 2004;25(2):487–91.

    CAS  PubMed  Google Scholar 

  53. Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006;97(12):1374–80.

    CAS  PubMed  Google Scholar 

  54. Yabe H, Tsukahara T, Kawaguchi S, Wada T, Torigoe T, Sato N, et al. Prognostic significance of HLA class I expression in Ewing’s sarcoma family of tumors. J Surg Oncol. 2011;103(5):380–5.

    CAS  PubMed  Google Scholar 

  55. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308.

    PubMed Central  CAS  PubMed  Google Scholar 

  56. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  57. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318–21.

    CAS  PubMed  Google Scholar 

  58. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155(6):1823–41.

    CAS  PubMed  Google Scholar 

  59. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984;225(4669):1487–9.

    CAS  PubMed  Google Scholar 

  60. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41(11 Pt 1):4420–5.

    CAS  PubMed  Google Scholar 

  61. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287–97.

    PubMed Central  CAS  PubMed  Google Scholar 

  62. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–92.

    CAS  PubMed  Google Scholar 

  63. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O’Connell M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76(5):824–32.

    CAS  PubMed  Google Scholar 

  64. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 2008;9(5):486–94.

    CAS  PubMed  Google Scholar 

  65. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 2013;11:83.

    PubMed Central  CAS  PubMed  Google Scholar 

  66. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21(13):1673–9.

    CAS  PubMed  Google Scholar 

  67. Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Different checkpoints in human NK-cell activation. Trends Immunol. 2004;25(12):670–6.

    CAS  PubMed  Google Scholar 

  68. Bottino C, Moretta L, Pende D, Vitale M, Moretta A. Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol Immunol. 2004;41(6–7):569–75.

    CAS  PubMed  Google Scholar 

  69. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997;18(2):89–95.

    CAS  PubMed  Google Scholar 

  70. Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237–44.

    CAS  PubMed  Google Scholar 

  71. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010;16(15):3901–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  72. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004;114(3):379–88.

    PubMed Central  CAS  PubMed  Google Scholar 

  73. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000;192(11):1637–44.

    PubMed Central  CAS  PubMed  Google Scholar 

  74. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163(1):507–13.

    CAS  PubMed  Google Scholar 

  75. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995;55(15):3369–73.

    CAS  PubMed  Google Scholar 

  76. Jungbluth AA, Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer. 2001;94(2):252–6.

    CAS  PubMed  Google Scholar 

  77. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–24.

    PubMed Central  PubMed  Google Scholar 

  78. Weibo P, Zhaoming Y. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma. Med Hypotheses. 2012;78(5):616–8.

    PubMed  Google Scholar 

  79. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–4.

    PubMed Central  CAS  PubMed  Google Scholar 

  80. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009;17(10):1779–87.

    PubMed Central  CAS  PubMed  Google Scholar 

  81. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.

    CAS  PubMed  Google Scholar 

  82. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100(14):8372–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  83. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23(25):6043–53.

    PubMed Central  CAS  PubMed  Google Scholar 

  84. Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A. 1999;96(20):11476–81.

    PubMed Central  CAS  PubMed  Google Scholar 

  85. Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D’Adamo DR, Keohan ML, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013;2013:168145.

    PubMed Central  PubMed  Google Scholar 

  86. Kawano M, Itonaga I, Iwasaki T, Tsumura H. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Oncol Rep. 2013;29(3):1001–6.

    CAS  PubMed  Google Scholar 

  87. Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011;30(12):1051–5.

    CAS  PubMed  Google Scholar 

  88. Feng D, Yang X, Li S, Liu T, Wu Z, Song Y, et al. Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing’s sarcoma. Gen Test Mol Biomark. 2013;17(6):458–63.

    CAS  Google Scholar 

  89. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010;37(5):430–9.

    CAS  PubMed  Google Scholar 

  90. Peng W, Lizee G, Hwu P. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Oncoimmunology. 2013;2(2):e22691.

    PubMed Central  PubMed  Google Scholar 

  91. Ge Y, Xi H, Ju S, Zhang X. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett. 2013;336(2):253–9.

    CAS  PubMed  Google Scholar 

  92. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73(12):3591–603.

    PubMed Central  CAS  PubMed  Google Scholar 

  93. So EY, Ouchi T. The application of toll like receptors for cancer therapy. Int J Biol Sci. 2010;6(7):675–81.

    PubMed Central  CAS  PubMed  Google Scholar 

  94. Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C, et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 2011;71(5):1607–14.

    CAS  PubMed  Google Scholar 

  95. Kanczkowski W, Morawietz H, Ziegler CG, Funk RH, Schmitz G, Zacharowski K, et al. Pam3CSK4 and LTA-TLRs ligands associated with microdomains induce IL8 production in human adrenocortical cancer cells. Horm Metab Res. 2007;39(6):457–60.

    CAS  PubMed  Google Scholar 

  96. Lombardi V, Van Overtvelt L, Horiot S, Moussu H, Chabre H, Louise A, et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy. 2008;38(11):1819–29.

    CAS  PubMed  Google Scholar 

  97. Yuk JM, Shin DM, Song KS, Lim K, Kim KH, Lee SH, et al. Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. Autophagy. 2010;6(1):46–60.

    CAS  PubMed  Google Scholar 

  98. Zanin-Zhorov A, Nussbaum G, Franitza S, Cohen IR, Lider O. T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors. FASEB J. 2003;17(11):1567–9.

    CAS  PubMed  Google Scholar 

  99. Taura M, Fukuda R, Suico MA, Eguma A, Koga T, Shuto T, et al. TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. Cancer Sci. 2010;101(7):1610–7.

    CAS  PubMed  Google Scholar 

  100. Jasani B, Navabi H, Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine. 2009;27(25–26):3401–4.

    CAS  PubMed  Google Scholar 

  101. Hennessy EJ, Parker AE, O’Neill LA. Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9(4):293–307.

    CAS  PubMed  Google Scholar 

  102. Geng D, Zheng L, Srivastava R, Velasco-Gonzalez C, Riker A, Markovic SN, et al. Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res. 2010;70(19):7442–54.

    PubMed Central  CAS  PubMed  Google Scholar 

  103. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013;309(11):1154–62.

    CAS  PubMed  Google Scholar 

  104. Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, et al. Structural basis of TLR5-flagellin recognition and signaling. Science. 2012;335(6070):859–64.

    PubMed Central  CAS  PubMed  Google Scholar 

  105. Cataldi A, Yevsa T, Vilte DA, Schulze K, Castro-Parodi M, Larzabal M, et al. Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine. 2008;26(44):5662–7.

    CAS  PubMed  Google Scholar 

  106. Schill T, Schon MP, Pletz N, Emmert S, Schon M. Stimulation of pulmonary immune responses by the TLR2/6 agonist MALP-2 and effect on melanoma metastasis to the lung. Exp Dermatol. 2012;21(2):91–8.

    CAS  PubMed  Google Scholar 

  107. Singh VK, Ducey EJ, Fatanmi OO, Singh PK, Brown DS, Purmal A, et al. CBLB613: a TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure. Radiat Res. 2012;177(5):628–42.

    CAS  PubMed  Google Scholar 

  108. Berman B, Poochareon VN, Villa AM. Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin Ther Lett. 2002;7(9):1–6.

    CAS  Google Scholar 

  109. Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V, et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res. 2008;14(3):856–64.

    CAS  PubMed  Google Scholar 

  110. Lu Z. Potential therapeutic interventions on toll like receptors for clinical applications. Res Pharm Biotechnol. 2010;2(1):7–13.

    Google Scholar 

  111. Hamm S, Rath S, Michel S, Baumgartner R. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol. 2009;6(4):257–65.

    CAS  PubMed  Google Scholar 

  112. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs. 2007;21(6):387–401.

    CAS  PubMed  Google Scholar 

  113. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27(2):161–7.

    CAS  PubMed  Google Scholar 

  114. Basith S, Manavalan B, Lee G, Kim SG, Choi S. Toll-like receptor modulators: a patent review (2006–2010). Exp Opin Ther Pat. 2011;21(6):927–44.

    CAS  Google Scholar 

  115. Tarhini AA, Kirkwood JM, Krieg AM. Early development of the toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. Expert Opin Drug Discov. 2009;4(5):587–603.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This manuscript was supported in part by Roswell Park Cancer Institute and National Cancer Institute (P30 CA016056).

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA

    Julie A. Alosi MD, Scott W. Baldwin MD, Jacqueline Oxenberg DO & Joseph J. Skitzki MD

  2. Department of Surgical Oncology, Geisinger Wyoming Valley Hospital, Wilkes-Barre, PA, 18702, USA

    Jacqueline Oxenberg DO

  3. Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA

    Joseph J. Skitzki MD

Authors
  1. Julie A. Alosi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott W. Baldwin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacqueline Oxenberg DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joseph J. Skitzki MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph J. Skitzki MD .

Editor information

Editors and Affiliations

  1. Children's Medical Center, Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Alosi, J.A., Baldwin, S.W., Oxenberg, J., Skitzki, J.J. (2015). Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas. In: Rezaei, N. (eds) Cancer Immunology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46410-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-46410-6_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-46409-0

  • Online ISBN: 978-3-662-46410-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation